This clinical quiz will test your knowledge on management of LDL-C special populations with nonstatin therapies based on the ACC's 2022 expert clinical decision pathway.
This clinical quiz will test your knowledge on the use of non-statin therapies for LDL-C lowering based on the American College of Cardiology's 2022 Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.
AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
The new guidance addresses the role of nonstatin therapies for lowering LDL-C, which were not addressed in the 2018 ACC/AHA guideline on management of cholesterol.